* serious chronic diseases or uncontrolled diseases; * uncontrolled neurological disorders, epilepsy; * received any inactivated vaccine within 1 week or received any attenuated vaccines within 4 weeks; * patients with congenital or acquired immunodeficiency; * history of severe allergy or be allergic to any components of the test vaccines; * history of hereditary hemorrhagic tendency or coagulation dysfunction; * patients with malignant tumors and other patients have a life expectancy less than 1 year; * refuse to sign the informed consent form or inability to complete follow-ups as required by the protocol; * history of previous covid-19 infection; * pregnant or breastfeeding women, or females of childbearing potential who not agree to or able to take effective and acceptable contraceptive methods during the study; * participants who have participated in other clinical trials within 3 months or are participating in other clinical trials; * those considered by the investigator as inappropriate to participate in the study.

* serious chronic diseases or uncontrolled diseases; * uncontrolled neurological disorders, epilepsy; * received any inactivated vaccine within 1 week or received any attenuated vaccines within 4 weeks; * patients with congenital or acquired immunodeficiency; * history of severe allergy or be allergic to any components of the test vaccines; * history of hereditary hemorrhagic tendency or coagulation dysfunction; * patients with malignant tumors and other patients have a life expectancy less than 1 year; * refuse to sign the informed consent form or inability to complete follow-ups as required by the protocol; * history of previous covid-19 infection; * pregnant or breastfeeding women, or females of childbearing potential who not agree to or able to take effective and acceptable contraceptive methods during the study; * participants who have participated in other clinical trials within 3 months or are participating in other clinical trials; * those considered by the investigator as inappropriate to participate in the study.

serious chronic diseases or uncontrolled diseases; uncontrolled neurological disorders, epilepsy; received any inactivated vaccine within 1 week or received any attenuated vaccines within 4 weeks; patients with congenital or acquired immunodeficiency; history of severe allergy or be allergic to any components of the test vaccines; history of hereditary hemorrhagic tendency or coagulation dysfunction; patients with malignant tumors and other patients have a life expectancy less than 1 year; refuse to sign the informed consent form or inability to complete follow-ups as required by the protocol; history of previous covid-19 infection; pregnant or breastfeeding women, or females of childbearing potential who not agree to or able to take effective and acceptable contraceptive methods during the study; participants who have participated in other clinical trials within 3 months or are participating in other clinical trials; those considered by the investigator as inappropriate to participate in the study.

serious chronic diseases or uncontrolled diseases; uncontrolled neurological disorders, epilepsy; received any inactivated vaccine within 1 week or received any attenuated vaccines within 4 weeks; patients with congenital or acquired immunodeficiency; history of severe allergy or be allergic to any components of the test vaccines; history of hereditary hemorrhagic tendency or coagulation dysfunction; patients with malignant tumors and other patients have a life expectancy less than 1 year; refuse to sign the informed consent form or inability to complete follow-ups as required by the protocol; history of previous covid-19 infection; pregnant or breastfeeding women, or females of childbearing potential who not agree to or able to take effective and acceptable contraceptive methods during the study; participants who have participated in other clinical trials within 3 months or are participating in other clinical trials; those considered by the investigator as inappropriate to participate in the study.